Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

236 Clinical Updates found
Urologic surgeon speaking with patient
A large cohort of patients with high-risk bladder cancer who underwent radical cystectomy and urinary tract reconstruction at Memorial Sloan Kettering Cancer Center reported favorable recovery and health-related quality of life within 24 months across most outcome measures.
HiSeq 2500 Ultra-High-Throughput Sequencing System powers MSK-IMPACT
Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with brain tumors.
ASCO logo sign at meeting
Memorial Sloan Kettering Cancer Center (MSK) experts presented breakthrough findings in several areas of cancer research at the 2022 Annual ASCO meeting, focusing on rectal, breast, leptomeningeal metastasis, pancreatic, and lung cancers.
Rectal Cancer Disappears After Experimental Use of Immunotherapy
Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.
Trastuzumab Deruxtecan (T-DXd) for Treating HER2-Low Breast Cancer Shows Promise
At the annual ASCO meeting, MSK medical oncologist Shanu Modi is presenting results from a clinical trial that found more people can benefit from a targeted therapy for breast cancer than previously thought.
By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.
Dr. Nancy Y. Lee
A study by Memorial Sloan Kettering (MSK) recently published in JAMA Oncology showed that radiation dose to the elective regions can be safely de-escalated for patients with human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) who received concurrent chemotherapy.
Vinod Balachandran, MD
Custom mRNA Vaccines for Pancreatic Cancer
Cancer vaccines that use messenger RNA (mRNA) technology are an exciting new approach to develop immunotherapies for cancers with poor prognoses, such as pancreatic cancer.
MSK's team of experts discussing advanced therapies available to treat acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia.
The oral menin inhibitor SNDX-5613 (Syndax Pharmaceuticals) demonstrated promising antileukemic activity and an acceptable safety profile in patients w...